Back to Search Start Over

An agarose-alginate microfluidic device for the study of spheroid invasion, ATRA inhibits CAFs-mediated matrix remodeling.

Authors :
Nasiraee MR
Shahrivari S
Sayad S
Mahdavi H
Saraygord-Afshari N
Bagheri Z
Source :
Cytotechnology [Cytotechnology] 2023 Aug; Vol. 75 (4), pp. 309-323. Date of Electronic Publication: 2023 Apr 11.
Publication Year :
2023

Abstract

Growing evidence demonstrates that cancer-associated fibroblasts (CAF) are responsible for tumor genesis, growth, metastasis, and treatment response. Therefore, targeting these cells may contribute to tumor control. It has been proposed that targeting key molecules and pathways of proliferative functions can be more effective than killing CAFs. In this regard, multicellular aggregates, like spheroids, can be used as human tumor models. Spheroids closely resemble human tumors and mimic many of their features. Microfluidic systems are ideal for cultivation and study of spheroids. These systems can be designed with different biological and synthetic matrices in order to have a more realistic simulation of the tumor microenvironment (TME). In this study, we investigated the effect of all-trans retinoic acid (ATRA) on 3D spheroid invasion of MDA-MB cells exposed to hydrogel matrix derived from CAFs. The number of invasive cells significantly decreased in CAF-ECM hydrogel treated with ATRA (pā€‰<ā€‰0.05), which indicates that ATRA could be effective for CAFs normalization. This experiment was done using an agarose-alginate microfluidic chip. As compared with common methods, such hydrogel casting is an easier method for chip fabrication and can even reduce costs.<br />Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-023-00578-y.<br />Competing Interests: Conflict of interestThe authors have no competing interests as defined by the journal, or other interests that might be perceived to influence the results and/or discussion reported in this paper.<br /> (© The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)

Details

Language :
English
ISSN :
0920-9069
Volume :
75
Issue :
4
Database :
MEDLINE
Journal :
Cytotechnology
Publication Type :
Academic Journal
Accession number :
37389131
Full Text :
https://doi.org/10.1007/s10616-023-00578-y